Abstract: Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.
Type:
Application
Filed:
February 7, 2024
Publication date:
October 3, 2024
Applicants:
Celgene Corporation, Bristol-Myers Squibb Company
Inventors:
Laura Akullian D'Agostino, Godwin Kumi, Haibo Liu
Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
Type:
Grant
Filed:
March 16, 2023
Date of Patent:
October 1, 2024
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
Type:
Grant
Filed:
June 24, 2022
Date of Patent:
October 1, 2024
Assignee:
Celgene Corporation
Inventors:
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1? blocker.
Type:
Grant
Filed:
November 4, 2020
Date of Patent:
September 17, 2024
Assignee:
Celgene Corporation
Inventors:
Tonia Buchholz, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, Tsun-Wen Yao
Abstract: The present disclosure relates to methods of using antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs in combination with a gamma secretase inhibitor (GSI), such as in therapeutic methods. Also provided are pharmaceutical compositions and kits comprising the antibody conjugates and GSI.
Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-? (SIRP?) and modulate the activity of SIRP?.
Type:
Grant
Filed:
February 1, 2023
Date of Patent:
September 10, 2024
Assignee:
Celgene Corporation
Inventors:
Mahan Abbasian, Henry H. Chan, Laure Escoubet, Gustavo Fenalti, Kandasamy Hariharan, Monica Wai Ling Leung, Konstantinos Mavrommatis, David P. Mikolon, Heather K. Raymon, Carlo Steven Santos, Jeonghoon Sun, Christina Valerie Trout
Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
Abstract: A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising obtaining a sample from the subject and measuring the gene expression level of IKZF3 and/or the gene expression levels of IFI27, IFI44, IFI44L, and RSAD2 in the sample.
Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.
Type:
Grant
Filed:
August 30, 2023
Date of Patent:
August 20, 2024
Assignee:
Celgene Corporation
Inventors:
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
Type:
Application
Filed:
January 25, 2024
Publication date:
August 15, 2024
Applicant:
Celgene Corporation
Inventors:
Jeffrey M. Schkeryantz, Karin Worm, Rulin Ma, Patrick W. Papa
Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) provided herein, in treating, preventing or managing multiple myeloma.
Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
Type:
Grant
Filed:
April 24, 2023
Date of Patent:
August 6, 2024
Assignee:
CELGENE CORPORATION
Inventors:
Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
Abstract: Provided herein are methods of treating multiple myeloma, comprising administering to a subject with multiple myeloma an inhibitor of Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Also provided are methods of use wherein the multiple myeloma has previously been determined to have a 4:14 chromosome translocation (t(4;14)).
Type:
Application
Filed:
February 25, 2022
Publication date:
July 11, 2024
Applicant:
Celgene Corporation
Inventors:
Nicholas Stong, Patrick R. Hagner, William Edward Pierceall, Anjan Thakurta, Jennifer Erin Flynt, Maria Ortiz-Estevez
Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
Type:
Grant
Filed:
November 8, 2021
Date of Patent:
July 9, 2024
Assignee:
Celgene Corporation
Inventors:
Matthew D. Alexander, Gerald D. Artman, Gordon L. Bray, James Carmichael, Soraya Carrancio, Brian E. Cathers, Matthew D. Correa, Joshua Hansen, Courtney G. Havens, Timothy S. Kercher, Antonia Lopez-Girona, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Rama K. Narla, Joseph R. Piccotti, Daniel W. Pierce, Paula A. Tavares-Greco, Brandon W. Whitefield, Lilly L. Wong, Nanfei Zou
Abstract: Provided herein are methods, compositions, and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA). In some aspects, the present disclosure relates to certain combination therapies that include administration of a cell therapy, such as a BCMA-targeted T cell therapy, in combination with immunomodulatory agents and other agents, such as dexamethasone, including for the treatment of subjects with multiple myeloma. In some embodiments, the multiple myeloma is a relapsed or refractory multiple myeloma.
Type:
Application
Filed:
April 15, 2022
Publication date:
June 27, 2024
Applicant:
Celgene Corporation
Inventors:
Julie Ann RYTLEWSKI, Gianfranco PITTARI
Abstract: Provided herein are methods of treating multiple myeloma, comprising administering to a subject with multiple myeloma an inhibitor of Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Also provided are methods of use wherein the multiple myeloma has previously been determined to have a 4:14 chromosome translocation (t(4;14)).
Type:
Application
Filed:
February 25, 2022
Publication date:
April 25, 2024
Applicant:
Celgene Corporation
Inventors:
Nicholas Stong, Patrick R. Hagner, William Edward Pierceall, Anjan Thakurta, Jennifer Erin Flynt, Maria Ortiz-Estevez
Abstract: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.
Abstract: Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein (referred to herein as “Heterocyclic Compounds”), compositions comprising an effective amount of a Heterocyclic Compound, as well as methods of preventing and/or treating cryptosporidiosis and/or inhibiting a parasite or parasitic activity.
Type:
Application
Filed:
December 27, 2021
Publication date:
April 18, 2024
Applicant:
Celgene Corporation
Inventors:
Dale E. Robinson, Natalie Hawryluk, Stacie Canan
Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
Type:
Application
Filed:
December 22, 2021
Publication date:
April 18, 2024
Applicant:
Celgene Corporation
Inventors:
Jeffrey M. Schkeryantz, Julie Selkirk, Philip Stewart Turnbull, Junko Tamiya, Patrick W. Papa, Jean-Francois Brazeau, Karin Worm